 |
|
|
| |
Treat HIV Early for Prevention (HPTN-052 TaSP)
and for Treatment (START) - PrEP too
|
| |
| |
from Jules: This is the top story coming out of IAS Vancouver - PREVENTION - 3 arms of prevention out of IAS 2015 are the 3 major stories: PrEP, START Study showing early ART (higher CD4) is superior to delaying ART [decreases mortality and comorbidities & preserves health] AND HPTN 052 is the study that shows early ART prevents transmission of HIV.
IAS/2015: Antiretroviral Treatment Prevents HIV Transmission: Final Results from the HPTN 052 Randomized Controlled Trial - (07/22/15)
IAS: Treatment as Prevention: Characterization of partner infections in the HIV Prevention Trials Network 052 trial - (07/27/15)
IAS/2015: Early ART Cuts HIV Transmission Rate 93% Through 2015 in HPTN 052 - written by Mark Mascolini - (07/22/15)
IAS/2015: Strategic Timing of AntiRetroviral Treatment (START) Study Primary Results - (07/22/15)
IAS/2015: START Trial: Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection......The START trial was designed and conducted by the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)..... - (07/24/15) NEJM - "The results support global goals set by the World Health Organization and the Joint United Nations Programme on HIV/AIDS to expand the use of antiretroviral therapy to all HIV-positive patients in order to improve their health and as part of efforts to reduce the future spread of HIV.22-24,47,48"
"In conclusion, we found a significant benefit in the immediate initiation of antiretroviral therapy in patients with HIV infection regardless of CD4+ count."....."A beneficial effect of immediate antiretroviral therapy was evident for both serious AIDS-related and serious non-AIDS-related events, and no increased rate of adverse effects associated with this strategy was observed.....The composite primary end point was reported in 42 patients in the immediate-initiation group and in 96 in the deferred-initiation group (Table 2 and Figure 2a). The estimated hazard ratio in the immediate-initiation group, as compared with the deferred-initiation group, was 0.43 (95% confidence interval [CI], 0.30 to 0.62; P<0.001)"
START - here WHO discuss the process & timeline regarding Guidelines for implementing results of START, early ART and WHO discusses implementation of PrEP
Panel discussion: the implications from the START findings
D. Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States
G. Hirnschall, World Health Organization, Switzerland
S. Abdool Karim, Centre for the AIDS Programme of Research in South Africa, South Africa
Z. Wu, Chinese Center for Diseases Control and Prevention, China
K. Thomson, The Global Fund to fight AIDS, Tuberculosis and Malaria, Switzerland
https://www.youtube.com/watch?t=25&v=miM3umStJFE
IAS 2015: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention
Vancouver Canada 18-22 July 2015
|
| |
|
|
|
|
|
